StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Manas Jaiswal

BUYZydus Lifesciences Limited

byManas JaiswalHorizon: NA (inferred Swing (≤2wk))7 Sept 2026via CNBC Awaaz.

Entry₹1,161.7Inferred
Target₹1,200
Total upside +3.30% (call closed)
Stop loss₹1,124-3.25% risk
Exit₹1,124Stop-loss hit — time not yet verified
Stop-loss hit-3.25%
Follow Manas Jaiswal for new calls(33% target hit, 283 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 268 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 10 Sept, 12:22 pm IST
5 supporting1 neutral0 opposing
Supports the BUY call (5)

MACD above its signal line — bullish momentum

Technicals · macd·10 Sept · today

India's Pharma Market Expands 10.7% On GLP-1 Launch: Zydus, Glenmark Lead Large-Cap Growth

NewsNdtv-Profit·9 Sept · today

(opens in new tab)

Zydus Lifesciences announced positive topline results from the completed EVIDENCES-X Phase II(b) clinical trial of Saroglitazar Mg for MASH.

BSE · Company Update·31 Aug · 1w ago

(opens in new tab)

Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating. Here's Why

NewsNdtv-Profit·27 Aug · 2w ago

(opens in new tab)

1 advisor has an active short-term BUY call on this stock

Advisor consensus · adjacent horizon·12 Aug · 4w ago

Neutral / worth noting (1)

Zydus Pharmaceuticals USA Inc., a subsidiary of Zydus Lifesciences, has agreed to pay USD 5.9 million to settle litigation in the US District Court for the Eastern District of Pennsylvania. The settle

BSE · Company Update·5 Sept · 4d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.